XPENG INC.

Where It Passes

Where It Falls Short

• Profitability0% pass✓ 5✗ 30▾

  No clean pass — all 16 investors flag at least one profitability criterion

  Positive EPS (10 years)0/9 years positive

  ✗GrahamPositive EPS every year for 10 years

  EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)

  ✗Graham>= 33% growth

  Net Income Positive (10+ years)0/9 years positive

  ✗BuffettPositive every year for 10+ years

  ROE (up to 5-year arithmetic mean)-17.4%

  ✗Buffett> 15% arithmetic mean (app rule)

  Operating Margin (10-yr trend)-3.6% (latest)

  ✓BuffettStable or rising over 10 years

  Free Cash Flow Proxy

  ✗BuffettPositive and growing

  Earnings Variance (10-yr CoV)N/A (negative mean EPS)

  ✗BuffettCoV < 0.3

  Retained Earnings Effectiveness

  ✗Buffett$1 retained -> > $1 market value created

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  3-5 Year EPS CAGR

  ✗Lynch15-30% (Fast Grower); > 0% to pass

  ROE-3.8%

  ✗Lynch> 15%

  EBIT / Enterprise Value-4.8%

  ✗Greenblatt> 10%

  Earnings Yield + ROC AssessmentEY=-4.8%, ROC=-37.2%

  ✗GreenblattBoth EY > 10% and ROC > 25%

  Net Income / Total Assets-1.10%

  ✗PiotroskiROA > 0

  ROA Change YoY-7.00% -> -1.10% (delta: +5.90%)

  ✓PiotroskiCurrent ROA > Prior ROA

  (CFO / Total Assets) vs ROACFO/Assets=8.01%, ROA=-1.10%

  ✓PiotroskiCFO/Assets > ROA

  Gross Margin Change YoY14.3% -> 18.9%

  ✓PiotroskiImproved YoY

  Pre-Tax Income / Revenue-1.5%

  ✗Dreman>= 8%

  Net Income / Shareholders' Equity-3.8%

  ✗Dreman> 12%

  Margin of SafetyP/B=4.1x

  ✗PabraiP/B < 1.5 or P/E < 15

  Return on Equity-16.9% (3-yr avg)

  ✗AkreROE > 20% (3-year avg)

  Discount to Intrinsic ValueN/A (negative normalized EPS)

  ✗Marks>= 20% below intrinsic value

  Positive Net Income Frequency0/8 years positive

  ✗MarksPositive net income in >= 7 of last 10 years

  Operating Income / Revenue-3.6%

  ✗Ackman>= 15%

  Net Income / Shareholders Equity-3.8%

  ✗Ackman>= 15%

  5-Year EPS CAGR

  ✗Templeton> 0% (5-year EPS CAGR)

  Operating Margin Trend-35.5% (2023) -> -3.6% (2025)

  ✓TempletonNon-negative operating-margin trend over 3 years

  Revenue growth vs. gross and operating margin trendgross margin 1.5% -> 18.9%, operating margin -35.5% -> -3.6%

  ✗SleepRevenue rising; gross margin flat or falling; operating margin holding

  Net income / market capitalization-1.81%; #3528/6340 (top 55.6%)

  ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section

  Gross profit / total assets+14.03%; #2486/3702 (top 67.2%)

  ✗AsnessTop 30% of eligible cross-section

  Net income / positive book equity-3.75%; #3146/5226 (top 60.2%)

  ✗AsnessTop 30% of eligible cross-section

  Negative 5-year standard deviation of ROA-0.0425; #2360/5884 (top 40.1%)

  ✗AsnessTop 30% of eligible cross-section

  3-5 Year Diluted EPS CAGR

  ✗Neff7%-20% annualized

  Positive Diluted-EPS Years0/8 years positive

  ✗Schloss>= 70% positive over 5-10 observed years (app rule)
• Efficiency0% pass✓ 1✗ 10▾

  No clean pass — all 8 investors flag at least one efficiency criterion

  Current Ratio1.09

  ✗Graham>= 2.0

  ROIC (3-5 yr avg)-20.3%

  ✗Buffett> 10%

  ROIC - WACC-30.3%

  ✗BuffettPositive (WACC = 10%)

  EBIT / (NWC + Net Fixed Assets)-37.2%

  ✗Greenblatt> 25%

  Current Ratio Change YoY1.25 -> 1.09

  ✗PiotroskiIncreased YoY

  Revenue / Total Assets Change YoY0.49x -> 0.74x

  ✓PiotroskiImproved YoY

  Current Assets / Current Liabilities1.09

  ✗Dreman> 1.5

  Return on Invested Capital-5.1%

  ✗Munger> 15%

  ROIC (high and growing)FY2023: ROIC=-18.2%; FY2024: ROIC=-12.1%; FY2025: ROIC=-5.1%

  ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each

  Reinvestment Rate x ROICN/A (non-positive net income)

  ✗AkreReinvestment Rate * ROIC > 10%

  ROIC (5-year)0/5 years above 12% (latest -5.1%)

  ✗SleepROIC > 12% in a majority of years
• Valuation8% pass✓ 2✗ 26▾

  12 of 13 flag XPEV's valuation — Graham, Lynch, Greenblatt +9 more

  Price / 3-yr avg EPS

  ✗Graham<= 15x

  Price-to-Book Ratio4.1x

  ✗Graham<= 1.5x

  P/E x P/B

  ✗Graham<= 22.5

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  EBIT / Enterprise Value-4.8%

  ✗Greenblatt> 10%

  Earnings Yield + ROC AssessmentEY=-4.8%, ROC=-37.2%

  ✗GreenblattBoth EY > 10% and ROC > 25%

  Price / EPS

  ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)

  Price / (CFO / Shares)15.1x

  ✗Dreman< 8x

  Price / Book Value per Share4.1x

  ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)

  Valuation Reasonableness

  ✗MungerP/E < 25 or Owner Earnings Yield > 5%

  P/E or FCF YieldFCF Yield=8.1%

  ✗PabraiP/E < 15 or FCF Yield > 10%

  P/B or P/E vs. Historical AverageP/B=4.1x

  ✗MarksP/E < 15 or P/B < 2.0

  Discount to Intrinsic ValueN/A (negative normalized EPS)

  ✗Marks>= 20% below intrinsic value

  Price / FCF per Share24.5x

  ✓Ackman<= 25

  Price vs. Trailing Low103% of trailing low ($9.12)

  ✓Templeton<= 120% of trailing low (certified split-adjusted live window)

  Net income / market capitalization-1.81%; #3528/6340 (top 55.6%)

  ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section

  Positive book equity / market capitalization+0.4836; #2946/6449 (top 45.7%)

  ✗AsnessTop 30% of eligible cross-section

  Price / Diluted EPS

  ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)

  (EPS CAGR % + Dividend Yield %) / P/E

  ✗Neff> 0.7 (Neff's published traditional edge)

  Price / Tangible Book Value per Share4.79x

  ✗SchlossP/TBV <= 1.00x (app cutoff)

  Book Value per Share Change-67.4%

  ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)

  Revenue / market capitalization+1.2217; #1564/5247 (top 29.8%)

  ✗OshaughnessyTop 10% of eligible cross-section

  (Operating cash flow - capex) / market capitalization+8.13%; #980/4519 (top 21.7%)

  ✗OshaughnessyTop 10% of eligible cross-section

  Trailing six-month price return through the evaluation date-43.04%; #4922/6202 (top 79.4%)

  ✗OshaughnessyTop 10% of eligible cross-section
• Growth13% pass✓ 4✗ 9▾

  7 of 8 flag XPEV's growth — Graham, Lynch, Dreman +4 more

  EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)

  ✗Graham>= 33% growth

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  3-5 Year EPS CAGR

  ✗Lynch15-30% (Fast Grower); > 0% to pass

  Inventory Growth vs Revenue GrowthInv: 94.7% vs Rev: 95.8%

  ✓LynchInventory growth < Revenue growth

  EPS Growth Direction$-0.99 (2018) -> $-0.09 (2025)

  ✗DremanPositive over recent years

  EPS CAGR

  ✗Dreman> 5% annualized

  Positive Net Income Frequency0/8 years positive

  ✗MarksPositive net income in >= 7 of last 10 years

  3yr Median Revenue Growth29.7%

  ✓Ackman>= 5%

  Positive EPS Growth Frequency3/5 years with positive EPS growth

  ✓AckmanPositive EPS growth in >= 3 of last 5 years

  5-Year EPS CAGR

  ✗Templeton> 0% (5-year EPS CAGR)

  Revenue growth vs. gross and operating margin trendgross margin 1.5% -> 18.9%, operating margin -35.5% -> -3.6%

  ✗SleepRevenue rising; gross margin flat or falling; operating margin holding

  5-year Revenue CAGR65.0%

  ✓SleepCAGR > 7%

  3-5 Year Diluted EPS CAGR

  ✗Neff7%-20% annualized
• Verdicts13% pass✓ 2✗ 13▾

  Split decision: 12 FAIL · 2 NEUTRAL · 1 BUY · 1 PASS

  Overall verdict

  ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (3/7)✗GreenblattRank #2192•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✓AckmanBUY (7/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1941/2370 (Top 81.9%))✗NeffFAIL (2/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
• Debt & Leverage33% pass✓ 7✗ 8▾

  8 of 12 flag XPEV's debt & leverage — Graham, Buffett, Lynch +5 more

  Debt Levels0.42

  ✓MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3

  LT Debt vs Net Current AssetsLT Debt $941.8M vs NCA $734.8M

  ✗GrahamLT Debt <= Net Current Assets

  Debt/Equity & Interest CoverageD/E: 0.42, IC: -7.3x

  ✗BuffettD/E < 0.5 AND Interest Coverage > 5x

  Total Debt / Equity0.42

  ✗Lynch< 0.33

  Cash - Long-term Debt$1.5B

  ✓LynchPositive preferred

  LT Debt / Total Assets Change6.85% -> 6.39%

  ✓PiotroskiDecreased YoY

  Current Assets / Current Liabilities1.09

  ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)

  Total Debt / Shareholders' Equity0.42

  ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x

  Interest Coverage & Debt/EBITDAIC=-7.3x, D/EBITDA=N/A (D&A unavailable)

  ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x

  Total Debt / Shareholders Equity0.42

  ✓Ackman<= 1.0

  Negative debt-to-equity (higher means less debt)-0.4185; #2286/4210 (top 54.3%)

  ✗AsnessTop 30% of eligible cross-section
• Cash Flow40% pass✓ 6✗ 6▾

  6 of 10 flag XPEV's cash flow — Buffett, Dreman, Pabrai +3 more

  Free Cash Flow Proxy

  ✗BuffettPositive and growing

  FCF Positive and Growing$729.4M

  ✓LynchPositive and growing

  Operating Cash Flow$1.2B

  ✓PiotroskiCFO > 0

  (CFO / Total Assets) vs ROACFO/Assets=8.01%, ROA=-1.10%

  ✓PiotroskiCFO/Assets > ROA

  Price / (CFO / Shares)15.1x

  ✗Dreman< 8x

  P/E or FCF YieldFCF Yield=8.1%

  ✗PabraiP/E < 15 or FCF Yield > 10%

  FCF Positive1/8 years FCF positive

  ✗MarksPositive FCF in majority of recent years

  (OCF - CapEx) / Market Cap4.1%

  ✓Ackman>= 4%

  Price / FCF per Share24.5x

  ✓Ackman<= 25

  Positive Operating Cash Flow frequency2/8 years positive

  ✗SleepPositive OCF in >= 70% of available years

  Operating Cash Flow - Capital Expenditures$729.4M

  ✓Neff> $0 (app proxy for a strong fundamental case)

  (Operating cash flow - capex) / market capitalization+8.13%; #980/4519 (top 21.7%)

  ✗OshaughnessyTop 10% of eligible cross-section
• Valuation models50% pass✓ 1✗ 1▾

  Models split on XPEV at $9.37 — fair values range $6.98–$13.72

  Munger fair value$6.98

  ✗Munger-34.2% margin vs $9.37

  Ackman fair value$13.72

  ✓Ackman+31.7% margin vs $9.37